Literature DB >> 10622313

Selection of metastatic tumour phenotypes by host immune systems.

K Seymour1, S Pettit, E O'Flaherty, R M Charnley, J A Kirby.   

Abstract

Metastasis and the processes underlying this phenomenon make epithelial cancers so malignant. Local control of cancers by surgery is sometimes possible but locoregional and distant recurrence commonly lead to the failure of treatment with ensuing morbidity and mortality. Tumour cells express a range of new antigens during growth and there are opportunities for the host immune system to interact with these antigens. This immune interaction eliminates the tumour or allows selection of phenotypic variants. Cell phenotypes selected by an incomplete immune response resemble the cell type commonly associated with metastases. Thus we propose that the host immune system may be responsible for selection of this phenotype and progression of the disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10622313     DOI: 10.1016/s0140-6736(99)04435-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  5 in total

1.  Hypoxia/reoxygenation induction of monocyte chemoattractant protein-1 in melanoma cells: involvement of nuclear factor-kappaB, stimulatory protein-1 transcription factors and mitogen-activated protein kinase pathways.

Authors:  Manfred Kunz; Gisela Bloss; Reinhard Gillitzer; Gerd Gross; Matthias Goebeler; Ulf R Rapp; Stephan Ludwig
Journal:  Biochem J       Date:  2002-08-15       Impact factor: 3.857

2.  Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21.

Authors:  Isabel Maleno; Carmen Maria Cabrera; Teresa Cabrera; Laura Paco; Miguel Angel López-Nevot; Antonia Collado; Antonio Ferrón; Federico Garrido
Journal:  Immunogenetics       Date:  2004-07-16       Impact factor: 2.846

Review 3.  Evolving immunotherapeutic strategies in bladder and renal cancer.

Authors:  T R L Griffiths; J K Mellon
Journal:  Postgrad Med J       Date:  2004-06       Impact factor: 2.401

4.  Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy.

Authors:  Rafael Carretero; José M Romero; Francisco Ruiz-Cabello; Isabel Maleno; Felix Rodriguez; Francisco M Camacho; Luis M Real; Federico Garrido; Teresa Cabrera
Journal:  Immunogenetics       Date:  2008-06-11       Impact factor: 2.846

5.  T cell adhesion and cytolysis of pancreatic cancer cells: a role for E-cadherin in immunotherapy?

Authors:  J J French; J Cresswell; W K Wong; K Seymour; R M Charnley; J A Kirby
Journal:  Br J Cancer       Date:  2002-10-21       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.